Trial · NCT02128269
Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
NCT02128269, Phase 2, Terminated, Alexion Pharmaceuticals, Inc.; results first posted 2017-07-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome. Trials, record NCT02128269. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02128269
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
- NCT number
- NCT02128269
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 9 participants, actual
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Conditions
- Antiphospholipid (aPL)-Positive
- Interventions
- Study Drug- ALXN1007
- First posted
- 2014-05-01
- Last updated
- 2017-07-13
- Other registries' IDs
- eudract:2013-003588-73
- Results first posted
- 2017-07-13
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety and Tolerability of Intravenous (IV) ALXN1007 as Measured by Percentage of Patients Reporting Adverse Events | Treatment Period (24 weeks) |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Safety and Tolerability of Intravenous (IV) ALXN1007 as Measured by Percentage of Patients Reporting Adverse Events | Treatment Period (24 weeks) | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety and Tolerability of Intravenous (IV) ALXN1007 as Measured by Percentage of Patients Reporting Adverse Events | ALXN1007 | 8 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Treatment Period | STARTED | ALXN1007 | 9 | |
| Treatment Period | COMPLETED | ALXN1007 | 7 | |
| Treatment Period | NOT COMPLETED | ALXN1007 | 2 | |
| Follow-up | STARTED | ALXN1007 | 9 | |
| Follow-up | COMPLETED | ALXN1007 | 9 | |
| Follow-up | NOT COMPLETED | ALXN1007 | 0 |
Source ClinicalTrials.gov
Adverse events42
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | ALXN1007- Open Label Study | 1 | 9 | |
| other | Antiphospholipid syndrome | Blood and lymphatic system disorders | ALXN1007- Open Label Study | 1 | 9 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | ALXN1007- Open Label Study | 1 | 9 | |
| other | Tinnitus | Ear and labyrinth disorders | ALXN1007- Open Label Study | 1 | 9 | |
| other | Abdominal pain | Gastrointestinal disorders | ALXN1007- Open Label Study | 1 | 9 | |
| other | Colitis | Gastrointestinal disorders | ALXN1007- Open Label Study | 1 | 9 | |
| other | Enterocolitis | Gastrointestinal disorders | ALXN1007- Open Label Study | 1 | 9 | |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | ALXN1007- Open Label Study | 1 | 9 | |
| other | Haemorrhoids | Gastrointestinal disorders | ALXN1007- Open Label Study | 1 | 9 | |
| other | Hypoaesthesia oral | Gastrointestinal disorders | ALXN1007- Open Label Study | 1 | 9 |
1 to 10 of 42Source ClinicalTrials.gov
See all 42 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | ALXN1007- Open Label Study | 0 | 9 |
| Total, other adverse events | ALXN1007- Open Label Study | 8 | 9 |
| Total, serious adverse events | ALXN1007- Open Label Study | 2 | 9 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02128269
GET https://conductscience.org/api/trials/v1/NCT02128269/events?page=2